The immunosuppressive drug FK506 reveals an antimalarial activity. The mechanism of the drug action involves the molecular interaction with target proteins PfFKBP35 and PvFKBP35 from P. falciparum and P. vivax, respectively. Interestingly, non-immunosuppressive FK506 analogues also show antimalarial activities. This prompted us to attempt to develop potential small molecule antagonists that specifically target the parasite enzymes devoid of immunosuppressive activity. To this end, we have determined the three-dimensional structures of the FK506 binding domain (FKBD)
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School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551 of P. falciparum and P. vivax in unligand form and in complex with FK506.The structural studies reveal that the Plasmodium FKBPs have similar structural folds like the canonical FKBP folds (Figure 1 overleaf) , providing mechanistic insights into PfFKBP35 and PvFKBP35 with possible routes for rational antimalarial drug design targeting the Plasmodium FKBPs.
Conclusion
Our structure-guided drug screening efforts resulted in an identification of novel adamantanyl-based-antimalarial compound named Supradamal (SRA). SRA exhibits a nanomolar inhibitory activity in both peptidylprolyl cis-trans isomerase (PPIase) assay and growth of P. falciparum cultured in human erythrocytes. In particular, SRA appears to inhibit the trophozoite development.
Published: 20 October 2010
